Valar Labs
Using AI models trained on digital pathology images to help oncologists make smarter cancer treatment decisions
First Investment: 2025
Dentists and ENT physicians lack a fast, easy, reliable way to catch oral cancer in its early stages — which is why oral cancer is one of the costliest cancers to treat, with survival rates that haven’t budged in decades. OraLiva is working to change that, with an automated, AI-powered microfluidic platform that uses machine learning algorithms trained on millions of cell images to identify dysplasia and early malignancy in brush-biopsied cells with over 95 percent accuracy. The reimbursable procedure gives providers a minimally invasive way to detect oral cancer early, improve outcomes, and unlock new revenue.
